Monoclonal Antibodies Production, Diagnostic and Therapeutic Applications

Mahmoud, Zeinab; El-Gawad, AbdElhady RagabAbd; Abdel-Latef, Tamer; Hassan, Myada

doi:10.21608/smj.2018.39245

Monoclonal Antibodies Production, Diagnostic and Therapeutic Applications

Document Type : Original Article

Authors

¹ Department of clinical and chemical pathology, Sohag Faculty of Medicine, Sohag University.

² Department of Clinical and Chemical Pathology, Faculty of Medicine, Sohag University

³ Department of Clinical and Chemical pathology, Sohag Faculty of Medicine, Sohag University.

⁴ Department of Clinical Pathology, Faculty of Medicine, Sohag University.

10.21608/smj.2018.39245

Abstract

Introduction:Monoclonal antibody is an antibody that is specific for one antigen and is produced by a B-cell hybridoma. Hybridoma technology has been replaced by recombinant DNA technology and transgenic method (mice, plant and chickens). Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence and quantity of this substance and so monoclonal antibody has many diagnostic applications.
Aim of the work:To clarify the new methods for production of monoclonal antibodies and application of monoclonal antibodies in diagnostic and therapeutic approaches.
Conclusion:Hybridoma technology has been replaced by recombinant DNA technology and transgenic method (mice, plant and chickens). Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence and quantity of this substance and so monoclonal antibody has many diagnostic applications as in the analysis of cell surface and secreted molecules like CD molecules identification and identification of transcription factor FOXP3. Also, they have a role in the molecular genomics to identify the susceptible genes that predispose to development of autoimmune thyroid diseases.

Keywords

References

1. Abbas AK, and, Litchman AH. Basic Immunology "Function and disorder of the immune system". . Williams and Wilkins 2^ndEd:. 2007:279-83.

2. Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, et al. Monoclonal Antibodies: A Review. Current clinical pharmacology. 2018;13(2):85-99.

3. William P. Fundamental immunology, . Lippincott Raven 4th Ed:. 1998:101-4.

4. Hudson PJ, and, Souriau C. Engineered antibodies. 9: 129-134. Nat Med. 2003;9:129-34.

5. Chen Y, Kim SH, Shang Y, Guillory J, Stinson J, Zhang Q, et al. Barcoded se-quencing workflow for high throughout digitization of hybridoma antibody var-iable domain sequences. Journal of immunological methods. 2018;455:88-94.

6. Nissim A, and, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Exp Pharmacol. 2008;181:3-18.

7. Janeway CA. Immunobiology, Garland Science. 6th Ed: 1653-9. Janeway C.A. and Charles G. Immunobiology. Garland Science 5^thEd. 2005:1639-46.

8. Eleonora M, and, Papavasiliou F. Recombination and the Evolution of the Adaptive Immune System. PLoS Biology. 2003:(1): 16.

9. Pleass RJ, Moore SC, Stevenson L, Hviid L. Immunoglobulin M: Restrainer of Inflammation and Mediator of Immune Evasion by Plasmodium falciparum Malaria. Trends in parasitology 2016;32(2)::108-19.

10. Yang J, 1,, Shen M, H. Polyethylene glycol-mediated cell fusion. . Methods Mol Biol. 2006;325:59-66.

11. Dunn AL. Pathophysiology, diagnosis and prevention of arthropathy in pat-ients with haemophilia. Haemophilia. 2011;17(4):571-8.

12. Lafeber FP, Miossec P, Valentino LA. Physiopathology of haemophilic arthro-pathy. Haemophilia. 2008;14(Suppl 4):3-9.

13. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophy-laxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta orthopaedica Scand-inavica Supplementum.2010:Suppl 77:3-132.

14. Nieuwenhuizen L, Roosendaal G, Coeleveld K, Lubberts E, Biesma DH, Lafeber FP, et al. Haemarthrosis stim-ulates the synovial fibrinolytic system in haemophilic mice. Thromb Haemost. 2013;110(1):173-83.

15. Acharya SS, Kaplan RN, Macdonald D, Fabiyi OT, DiMichele D, Lyden D. Neoangiogenesis contributes to the development of hemophilic synovitis. Blood. 2011;117(8):2484-93.

16. Madhok R, Bennett D, Sturrock RD, Forbes CD. Mechanisms of joint damage in an experimental model of hemophilic arthritis. Arthritis Rheum.2011;31(9):1148-55.

17. Jansen NW, Roosendaal G, Bijlsma JW, Degroot J, Lafeber FP. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum. 2007;56(1):199-207.

18. Roosendaal G, Vianen ME, Marx JJ, van den Berg HM, Lafeber FP, Bijlsma JW. Blood-induced joint damage: a human in vitro study. Arthritis Rheum.2013;42(5):1025-32.

19. Stern M, and, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. . Crit Rev Oncol Hemato. 2005;154:11-29.

20. Narkbunnam N, Sun J, Hu G, Lin FC, Bateman TA, Mihara M, et al. IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia. J Thromb Haemost. 2013;11(5):881-93.

21. Geisberger R, Lamers M, Achatz G. "The riddle of the dual expression of IgM and IgD". . Immunology 2006;118(4):889–98. .

22. Roosendaal G, Vianen ME, Wenting MJ, van Rinsum AC, van den Berg HM, Lafeber FP, et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. The Journal of bone and joint surgery British volume.2008;80(3):540-5.

23. Roosendaal G, Lafeber FP. Patho-genesis of haemophilic arthropathy. Haemophilia. 2006;12 Suppl 3:117-21.

24. Raffini L, Manno C. Modern manage-ment of haemophilic arthropathy. Bri-tish journal of haematology. 2007;136(6):777-87.

25. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost. 2010;8(9):1895-902.

26. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. British journal of rheumatology.2013;34(4):321-5.

27. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology. 2008;47(11):1635-40.

28. Nissim A, and, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. . Exp Pharmacol 2008;181:3-18.

29. Feldman BM, Funk SM, Bergstrom BM, Zourikian N, Hilliard P, van der Net J, et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis care & research. 2011;63(2):223-30.

30. Santin AD, Bellone S, Roman J, McKenney J, and, Pecorelli S. Trastuzu-mab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER₂/neu. Int J Gynae-col Obstet 2008;102 (2):128-3l.

31. Folkman J, Shing Y. Angiogenesis. The Journal of biological chemistry.2006;267(16):10931-4.

32. Joseph-Silverstein J, Rifkin DB. Endo-thelial cell growth factors and the vessel wall. Seminars in thrombosis and hemo-stasis.2010;13(4):504-13.

33. Ortega N, Jonca F, Vincent S, Favard C, Ruchoux MM, Plouet J. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 sele-ctively triggers endothelial cells with an angiogenic phenotype. The American journal of pathology.2004;151(5):1215-24.

34. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endo-thelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. The Journal of biological chemistry.2010;272(38):23659-67.

35. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, and, et al. Long-term responses seen with ritu-ximab m patients with ITP. Community Oncology 2007;4(2):107.

36. Diaz-Torne C, Schumacher HR, Yu X, Gomez-Vaquero C, Dai L, Chen LX, et al. Absence of histologic evidence of syovitis in patients with Gulf War veterans' illness with joint pain. Arthritis Rheum. 2007;57(7):1316-23.

37. Krenn V, Morawietz L, Burmester GR, Kinne RW, Mueller-Ladner U, Muller B, et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology. 2006;49(4):358-64.

38. Krenn V, Morawietz L, Konig B, Otto M, Kriegsmann J, Kopenik A, et al. Low-grade/high-gradesynovitis: syno-vitis-sore as a gold standard?. Der Orthopade. 2006;35(8):853-9.

39. Pessler F, Chen LX, Dai L, Gomez-Vaquero C, Diaz-Torne C, Paessler ME, et al. A histomorphometric analysis of synovial biopsies from individuals with Gulf War Veterans' Illness and joint pain compared to normal and osteo-arthritis synovium. Clinical rheuma-tology. 2008;27(9):1127-34.

40. Della Beffa C, Slansky E, Pommerenke C, Klawonn F, Li J, Dai L, et al. The relative composition of the inflamma-tory infiltrate as an additional tool for synovial tissue classification. PLoS One. 2013;8(8):e72494.

41. Krenn V, Morawietz L, Haupl T, Neidel J, Petersen I, Konig A. Grading of chronic synovitis--a histopathological grading system for molecular and diag-nostic pathology. Pathology, research and practice. 2002;198(5):317-25.

42. Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, Bonnet V, et al. Rheuma-toid hand joint synovitis: gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-alpha treatment: pilot study. Radiology. 2003;229(2):562-9.

43. Reiche BE, Ohrndorf S, Feist E, Messerschmidt J, Burmester GR, Back-haus M. Power doppler ultrasound is useful for prediction of re-therapy with rituximab in rheumatoid arthritis. Arthritis care & research. 2013.

44. Iagnocco A, Epis O, Delle Sedie A, Meenagh G, Filippucci E, Riente L, et al. Ultrasound imaging for the rheuma-tologist. XVII. Role of colour Doppler and power Doppler. Clinical and experimental rheumatology. 2008;26(5):759-62.

45. Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen T, Ostergaard M. Power Doppler ultra-sonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: a comparison with dynamic magnetic resonance imaging. Arthritis Rheum. 2001;44(9):2018-23.

46. Dougados M, Devauchelle-Pensec V, Ferlet JF, Jousse-Joulin S, D'Agostino MA, Backhaus M, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Annals of the rheumatic diseases. 2013;72(5):665-71.

47. Naredo E, Batlle-Gualda E, Garcia-Vivar ML, Garcia-Aparicio AM, Fernandez-Sueiro JL, Fernandez-Prada M, et al. Power Doppler ultrasonogra-phy assessment of entheses in spondylo-arthropathies: response to therapy of entheseal abnormalities. The Journal of rheumatology. 2010;37(10):2110-7.